Prelude Therapeutics' Series A Round

Prelude Therapeutics raised a round of funding on July 11, 2016. Investors include OrbiMed Advisors.

Prelude Therapeutics is a privately held biotechnology company focused on discovering and developing new medicines targeting chromatin function to treat cancer and rare diseases.…

Articles about Prelude Therapeutics' Series A Round: